First oncolytic virus approved for melanoma immunotherapy

被引：290

作者：

Pol, Jonathan ^{[1
,2
,3
,4
,5
]}

Kroemer, Guido ^{[1
,2
,3
,4
,6
,7
,8
]}

Galluzzi, Lorenzo ^{[1
,2
,3
,4
,5
]}

机构：

[1] INSERM, U1138, Paris, France

[2] Univ Paris 05, Sorbonne Paris Cite, Paris, France

[3] Univ Paris 06, Paris, France

[4] Ctr Rech Cordeliers, Equipe Labellisee Ligue Natl Canc 11, Paris, France

[5] Gustave Roussy Canc Campus, Villejuif, France

[6] Hop Europeen Georges Pompidou, Pole Biol, AP HP, Paris, France

[7] Gustave Roussy Canc Campus, Metabol & Cell Biol Platforms, Villejuif, France

[8] Karolinska Univ Hosp, Dept Womens & Childrens Hlth, Stockholm, Sweden

来源：

ONCOIMMUNOLOGY | 2016年 / 5卷 / 01期

关键词：

Granulocyte macrophage colony-stimulating factor; Imlygic (R); OncoVEX(GM-CSF); OPTiM; talimogene laherparepvec; T-vec; HERPES-SIMPLEX-VIRUS; CELL-DEATH;

D O I：

10.1080/2162402X.2015.1115641

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

On 2015, October 27th, the US Food and Drug Administration (FDA) has officially approved talimogene laherparepvec (T-VEC, also known as OncoVEX(GM-CSF)) for use in melanoma patients with injectable but non-resectable lesions in the skin and lymph nodes. T-VEC (which is commercialized by Amgen, Inc. under the name of Imlygic (R)) becomes therefore the first oncolytic virus approved for cancer therapy in the US.

引用

页数：3

共 38 条

[1]

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma [J].

Andtbacka, Robert H. I. ;

Kaufman, Howard L. ;

Collichio, Frances ;

Amatruda, Thomas ;

Senzer, Neil ;

Chesney, Jason ;

Delman, Keith A. ;

Spitler, Lynn E. ;

Puzanov, Igor ;

Agarwala, Sanjiv S. ;

Milhem, Mohammed ;

Cranmer, Lee ;

Curti, Brendan ;

Lewis, Karl ;

Ross, Merrick ;

Guthrie, Troy ;

Linette, Gerald P. ;

Daniels, Gregory A. ;

Harrington, Kevin ;

Middleton, Mark R. ;

Miller, Wilson H., Jr. ;

Zager, Jonathan S. ;

Ye, Yining ;

Yao, Bin ;

Li, Ai ;

Doleman, Susan ;

VanderWalde, Ari ;

Gansert, Jennifer ;

Coffin, Robert S. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (25) :2780-U98

[2]

Immunostimulatory monoclonal antibodies in cancer therapy [J].

Aranda, Fernando ;

Vacchelli, Erika ;

Eggermont, Alexander ;

Galon, Jerome ;

Fridman, Wolf Herve ;

Zitvogel, Laurence ;

Kroemer, Guido ;

Galluzzi, Lorenzo .

ONCOIMMUNOLOGY, 2014, 3 (02)

[3]

Radioimmunotherapy for oncological indications [J].

Bloy, Norma ;

Pol, Jonathan ;

Manic, Gwenola ;

Vitale, Ilio ;

Eggermont, Alexander ;

Galon, Jerome ;

Tartour, Eric ;

Zitvogel, Laurence ;

Kroemer, Guido ;

Galluzzi, Lorenzo .

ONCOIMMUNOLOGY, 2014, 3 (09)

[4]

Cassady KA, 1998, J VIROL, V72, P7005

[5]

Antiviral prodrugs - the development of successful prodrug strategies for antiviral chemotherapy [J].

De Clercq, E ;

Field, HJ .

BRITISH JOURNAL OF PHARMACOLOGY, 2006, 147 (01) :1-11

[6]

Oncolytic Virus Immunotherapy for Melanoma [J].

Dharmadhikari, Neal ;

Mehnert, Janice M. ;

Kaufman, Howard L. .

CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2015, 16 (03)

[7]

Oncolytic viruses get a boost with first FDA-approval recommendation [J].

Dolgin, Elie .

NATURE REVIEWS DRUG DISCOVERY, 2015, 14 (06) :369-+

[8]

Essential versus accessory aspects of cell death: recommendations of the NCCD 2015 [J].

Galluzzi, L. ;

Bravo-San Pedro, J. M. ;

Vitale, I. ;

Aaronson, S. A. ;

Abrams, J. M. ;

Adam, D. ;

Alnemri, E. S. ;

Altucci, L. ;

Andrews, D. ;

Annicchiarico-Petruzzelli, M. ;

Baehrecke, E. H. ;

Bazan, N. G. ;

Bertrand, M. J. ;

Bianchi, K. ;

Blagosklonny, M. V. ;

Blomgren, K. ;

Borner, C. ;

Bredesen, D. E. ;

Brenner, C. ;

Campanella, M. ;

Candi, E. ;

Cecconi, F. ;

Chan, F. K. ;

Chandel, N. S. ;

Cheng, E. H. ;

Chipuk, J. E. ;

Cidlowski, J. A. ;

Ciechanover, A. ;

Dawson, T. M. ;

Dawson, V. L. ;

De laurenzi, V. ;

De Maria, R. ;

Debatin, K-M ;

Di Daniele, N. ;

Dixit, V. M. ;

Dynlacht, B. D. ;

El-Deiry, W. S. ;

Fimia, G. M. ;

Flavell, R. A. ;

Fulda, S. ;

Garrido, C. ;

Gougeon, M-L ;

Green, D. R. ;

Gronemeyer, H. ;

Hajnoczky, G. ;

Hardwick, J. M. ;

Hengartner, M. O. ;

Ichijo, H. ;

Joseph, B. ;

Jost, P. J. .

CELL DEATH AND DIFFERENTIATION, 2015, 22 (01) :58-73

[9]

Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents [J].

Galluzzi, Lorenzo ;

Buque, Aitziber ;

Kepp, Oliver ;

Zitvogel, Laurence ;

Kroemer, Guido .

CANCER CELL, 2015, 28 (06) :690-714

[10]

Classification of current anticancer immunotherapies [J].

Galluzzi, Lorenzo ;

Vacchelli, Erika ;

Bravo-San Pedro, Jose-Manuel ;

Buque, Aitziber ;

Senovilla, Laura ;

Baracco, Elisa Elena ;

Bloy, Norma ;

Castoldi, Francesca ;

Abastado, Jean-Pierre ;

Agostinis, Patrizia ;

Apte, Ron N. ;

Aranda, Fernando ;

Ayyoub, Maha ;

Beckhove, Philipp ;

Blay, Jean-Yves ;

Bracci, Laura ;

Caignard, Anne ;

Castelli, Chiara ;

Cavallo, Federica ;

Celis, Estaban ;

Cerundolo, Vincenzo ;

Clayton, Aled ;

Colombo, Mario P. ;

Coussens, Lisa ;

Dhodapkar, Madhav V. ;

Eggermont, Alexander M. ;

Fearon, Douglas T. ;

Fridman, Wolf H. ;

Fucikova, Jitka ;

Gabrilovich, Dmitry I. ;

Galon, Jerome ;

Garg, Abhishek ;

Ghiringhelli, Francois ;

Giaccone, Giuseppe ;

Gilboa, Eli ;

Gnjatic, Sacha ;

Hoos, Axel ;

Hosmalin, Anne ;

Jaeger, Dirk ;

Kalinski, Pawel ;

Kaerre, Klas ;

Kepp, Oliver ;

Kiessling, Rolf ;

Kirkwood, John M. ;

Klein, Eva ;

Knuth, Alexander ;

Lewis, Claire E. ;

Liblau, Roland ;

Lotze, Michael T. ;

Lugli, Enrico .

ONCOTARGET, 2014, 5 (24) :12472-12508

← 1 2 3 4 →